Published in Hematol Oncol Clin North Am on April 01, 2013
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 11.50
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med (1993) 3.64
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci (2005) 3.45
Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans (2006) 3.37
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood (2008) 3.19
P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09
Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood (2004) 2.71
Antigen receptors on B lymphocytes. Annu Rev Immunol (1992) 2.65
ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol (2006) 2.63
The role of PI3K in immune cells. Nat Immunol (2003) 2.41
p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem (1997) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2005) 1.91
BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood (2008) 1.78
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J (2012) 1.56
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia (2005) 1.46
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood (2011) 1.45
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res (2012) 1.33
Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol (2008) 1.20
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia (1997) 1.14
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia (2011) 1.09
Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death Differ (2005) 1.06
Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev (2009) 1.05
Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med (2008) 0.93
[Hematology 2008]. Dtsch Med Wochenschr (2008) 0.77
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant (2008) 1.69
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.46
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma (2012) 1.45
Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.43
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood (2012) 1.42
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest (2013) 1.30
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood (2008) 1.27
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One (2011) 1.12
Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol (2008) 1.07
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res (2014) 1.04
Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res (2011) 1.02
Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett (2012) 1.01
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol (2012) 1.00
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol (2014) 0.98
Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer (2010) 0.95
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res (2011) 0.93
Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet (2010) 0.89
Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol (2010) 0.88
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol (2014) 0.88
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.88
A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol (2014) 0.86
BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res (2012) 0.86
Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma. J Clin Oncol (2004) 0.85
Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet (2010) 0.83
Biopolymer and water dynamics in microbial biofilm extracellular polymeric substance. Biomacromolecules (2008) 0.83
Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk (2010) 0.81
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma (2013) 0.81
Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol (2010) 0.80
Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol (2010) 0.79
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma (2013) 0.78
Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells. Leuk Lymphoma (2015) 0.78
Magnetic resonance microscopy determined velocity and hematocrit distributions in a Couette viscometer. Biorheology (2005) 0.78
AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter. J Clin Oncol (2007) 0.78
Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs (2015) 0.76
Genomic approaches to chronic lymphocytic leukemia. Hematol Oncol Clin North Am (2013) 0.76
Microbial and algal alginate gelation characterized by magnetic resonance. J Biotechnol (2012) 0.76
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma (2014) 0.76
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res (2013) 0.75
ASCT in follicular lymphoma. Nat Rev Clin Oncol (2009) 0.75
Using Targeted Inhibitors in the Management of Chronic Lymphocytic Leukemia: Are We There Yet? Oncology (Williston Park) (2016) 0.75
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy. Oncology (Williston Park) (2015) 0.75
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]. Hematology Am Soc Hematol Educ Program (2011) 0.75
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma (2014) 0.75